Biofrontera Inc. (BFRI)
| Previous Close | 0.8764 |
| Open | 0.8928 |
| Bid | 0.9705 x 1400 |
| Ask | 0.9800 x 1800 |
| Day's Range | 0.8799 - 1.0400 |
| 52 Week Range | 0.8600 - 14.6300 |
| Volume | |
| Avg. Volume | 759,222 |
| Market Cap | 22.859M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5900 |
| Earnings Date | Apr 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Here's Why Biofrontera (NASDAQ:BFRI) Must Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has awarded the previously nominated Ameluz® marketing campaign, created by Biofrontera Inc. along with Elevate Healthcare, “Relaunch/Revitalization of the Year” and “Professio
- GlobeNewswire
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Gerard DiGirolamo as National Sales Director. In this newly created position, Mr. DiGirolamo will report to Mark Baldyga, Biofrontera’s Head of Sales & Marketing, and will help execute the Company’s U.S. sales division and objectives including the strategic design, expansion and leadership of
